Vericel Corp (VCEL)
45.32
-0.99
(-2.14%)
USD |
NASDAQ |
Apr 18, 11:18
Vericel Cash from Financing (TTM): 3.618M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 3.618M |
September 30, 2023 | 2.916M |
June 30, 2023 | 1.595M |
March 31, 2023 | 0.649M |
December 31, 2022 | 1.045M |
September 30, 2022 | 1.781M |
June 30, 2022 | 3.88M |
March 31, 2022 | 7.412M |
December 31, 2021 | 9.171M |
September 30, 2021 | 12.28M |
June 30, 2021 | 11.29M |
March 31, 2021 | 8.397M |
December 31, 2020 | 6.441M |
September 30, 2020 | 3.514M |
June 30, 2020 | 4.406M |
March 31, 2020 | 4.584M |
December 31, 2019 | 5.26M |
September 30, 2019 | -13.44M |
June 30, 2019 | -13.21M |
March 31, 2019 | 57.15M |
December 31, 2018 | 58.86M |
September 30, 2018 | 87.31M |
June 30, 2018 | 92.59M |
March 31, 2018 | 21.21M |
December 31, 2017 | 18.58M |
Date | Value |
---|---|
September 30, 2017 | 30.80M |
June 30, 2017 | 27.18M |
March 31, 2017 | 29.61M |
December 31, 2016 | 29.70M |
September 30, 2016 | 6.188M |
June 30, 2016 | 2.627M |
March 31, 2016 | 0.137M |
December 31, 2015 | -0.024M |
September 30, 2015 | -0.319M |
June 30, 2015 | 41.00M |
March 31, 2015 | 44.47M |
December 31, 2014 | 49.93M |
September 30, 2014 | 51.82M |
June 30, 2014 | 20.96M |
March 31, 2014 | 17.49M |
December 31, 2013 | 14.40M |
September 30, 2013 | 12.81M |
June 30, 2013 | 2.508M |
March 31, 2013 | 2.405M |
December 31, 2012 | 37.93M |
September 30, 2012 | 37.89M |
June 30, 2012 | 37.69M |
March 31, 2012 | 37.75M |
December 31, 2011 | -0.195M |
September 30, 2011 | -0.205M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-13.44M
Minimum
Sep 2019
12.28M
Maximum
Sep 2021
3.242M
Average
3.88M
Median
Jun 2022
Cash from Financing (TTM) Benchmarks
Arbutus Biopharma Corp | 30.65M |
Chimerix Inc | 0.308M |
Karyopharm Therapeutics Inc | 1.124M |
Axsome Therapeutics Inc | 331.01M |
Y-mAbs Therapeutics Inc | 0.10M |